Enable JavaScript to visit this website.
Skip directly to content

CUA and Pfizer Canada Award One Clinical Fellowship in Incontinence and Two CUA-Pfizer Urology Resident Grant Awards


July 18, 2018 – KIRKLAND , QC - Researcher Dr. Hilary L. Brotherhood is the recipient of 2018 fellowship program

The 2018 Canadian Urological Association Scholarship Foundation (CUASF) and Pfizer Canada Clinical Fellowship in Incontinence has been awarded to a Canadian urologist who has just completed her urology residency; Hilary Brotherhood will be completing her fellowship at University of Calgary, Division of Urology.  With this funding, she will conduct new projects in functional urology to improve support, education and treatment for patients with incontinence.

“Investigate TURP readmission rates in the Calgary Zone”
All Transurethral Resections of the Prostate (TURPs) in the Calgary Zone are performed at the Rockyview General Hospital (RGH). TURP is a common and high-volume procedure at the RGH and is indicated to treat lower urinary tract symptoms (LUTS) refractory to medical therapy, and to treat the sequelae of benign prostatic hyperplasia (BPH) such as urinary retention, bladder calculi, recurrent urinary tract infections, recurrent prostate bleeding and hydronephrosis and renal insufficiency. The RGH participates in the National Surgical Quality Improvement Program (NSQIP) and based on these data, there are reasons to be concerned with the rate of return to the ER and the hospital readmission rates after this procedure. The relatively-high return to ER and readmission rates observed in these data suggest an opportunity to improve the quality of care for these patients, and to reduce associated costs. Successfully accomplishing the objectives of this study – reducing the ER return and hospital readmission rates – will have a direct impact on the quality-of-life of patients undergoing TURPs in Calgary Zone. Thus, this study is well-aligned with the objective of the CUA-Pfizer Incontinence Fellowship Award to improve the burden of urological disorders, such as LUTS.

CUA-Pfizer Urology Resident Grant Program 2018 Winners
The CUA and Pfizer Canada has also recognized two residents for their outstanding research or care enhancement projects that promote excellence in urology with the ultimate goal of improving patient care or further understanding the biology of urologic diseases.




Dr. Louisa Ho

To validate a smartphone app-based acoustic uroflowmeter against a commercially available, standard Laborie uroflowmeter in a controlled clinical setting in an adult urology patient population

University of British Columbia


Dr. Marie-Pier St. Laurent

Canadian Experience with Contiform Intravaginal Device for the Treatment of Stress Incontinence: Effectiveness and Patient Acceptability

University of Laval


CUA– Pfizer Canada Research Program Past Awardees - Scientific Exchange Meeting
At #CUA18 in Halifax, Pfizer Canada hosted a Scientific Exchange luncheon for the CUA-Pfizer Fellowship/Resident past awardees. This congregation is an opportunity to highlight to past award winners the continued excellence in research within functional urology and further the understanding of how patient care can be improved, leading to positive impact on patients’ lives. The Scientific Exchange which took place on June 25, 2018 was a great opportunity to connect with all current Fellows, Residents and Past Awardees.

About the CUA - Pfizer Canada Clinical Fellowship in Incontinence
The CUA-Pfizer Incontinence Fellowship Award provides much needed funding to support Canadian urologists that have completed their RCPSC training successfully and are embarking on clinical fellowships. The financial support for these fellowships will result in many of the brightest young urologists in Canada furthering their training in centers of excellence around the world in the area of functional urology and bringing their advanced skill and knowledge set back to Canada. This will ultimately result in Canadians receiving the most comprehensive, innovative and contemporary care in incontinence.

“Urological disorders are a growing burden in Canada. These awarded projects and the grant program demonstrate a shared commitment by the CUA and Pfizer to ensure scientific discovery and innovation in the field of urology and specifically, incontinence,” says Dr. Jonathan Izawa, Chair of the Scientific Council of the Canadian Urological Association Scholarship Foundation (CUASF).

“Incontinence has an enormous impact on the quality of life of patients and can significantly alter their social interactions and increase their feeling of helplessness” says Dr. Vratislav Hadrava, Chief Medical Officer, Pfizer Canada. “Pfizer is proud to support Canadian urological researchers whose work contributes to improving the day-to-day lives of people living with urinary incontinence . The CUA-Pfizer Urology Fellowship and Resident Grant Programs are now in their six and third years of existence respectively. Pfizer looks forward to continuing to learn from Awardees how these fellowships and grants help Canadian Urology residents and young researchers to forward their research and care enhancement projects.”

A seventh year with new fellowship and resident opportunities will take place in 2019-2020. For more information on how to apply for 2019 grants, eligible research proposals, review criteria, notification dates and submission process please visit http://www.cua.org/en/training-scholarships.

About the CUA-Pfizer Urology Resident Grant Program
The CUA-Pfizer Urology Resident Grant Program is meant to support peer-reviewed competitive resident research or care enhancement projects that promote excellence in functional urology with the ultimate goal of improving patient care or further understanding the biology of urologic diseases. The financial support to Canadian urology residents may have great impact by allowing them to test novel hypotheses that established urologists might not have already considered.

About Canadian Urological Association
The Canadian Urological Association is a national member-based organization dedicated to enabling the profession to provide the highest possible standards of urologic care by collaboratively:

  • Fostering excellence in urologic practice through advocacy, education, research and practice support tools
  • Leading evidence-based clinical practice through the development of practice standards and guidelines
  • Providing continuous professional development for Canadian urologists along the career-path continuum
  • Providing leadership in public education for urologic conditions
  • Representing the Canadian urologic community in relationships with governments as well as national and international medical societies.

About Pfizer Canada
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, vaccines and consumer health products. Pfizer’s ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: Working together for a healthier worldTM. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).


For further information:

Corporate Affairs
Pfizer Canada
1-866-9PFIZER (973-4937)